EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TTV Viremia and Immune Responses Following Vaccination Against Mpox and Dengue Viruses

Claudia Minosse iD, Pietro Giorgio Spezia iD, Sara Belladonna, Aurora Bettini, Giulia Matusali iD, Francesca Colavita iD, Stefania Notari iD, Linda Petrone, Marta Tiberi, Alessandro Rosario Cavasio iD, Valentina Mazzotta iD, Luigi Rosa iD und 6 weitere

Vaccines · 15.05.2026 · 14 (5) · 441

DOI: 10.3390/vaccines14050441 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 15.05.2026. Verfasst von Claudia Minosse und 17 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Virology and Laboratories of Biosecurity, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, European Union Framework Programme for Research and Innovation Horizon 2020, Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Torquetenovirus (TTV) viremia is increasingly recognized as a biomarker of host immune competence. We assessed the association between baseline TTV DNA levels and immune responses to the Mpox virus (MPXV) and dengue virus (DGV) vaccines in two prospective cohorts.

Methods

A total of 248 individuals were enrolled, and TTV DNA was quantified before vaccination. Humoral and cellular responses to MVA-BN (for MPXV) and QDENGA (for DGV) vaccines were measured by using serology, neutralization assays, and interferon-γ ELISpot, and correlations with TTV viremia were investigated.

Results

TTV DNA was detected in 81.2% of individuals, with a significantly higher prevalence and viral loads in the Mpox-Vac group than in the DGV-Vac group. Between both groups, the only significant association observed was an inverse correlation between pre-vaccination TTV load and DGV neutralizing antibody titers in the DGV-Vac group and was limited to the subset of TTV-positive individuals; no additional correlations with antibody and T responses were identified. For the Mpox-Vac group, stratified analyses in people living with HIV (PLWH) confirmed this lack of association.

Conclusions

TTV viremia does not predict vaccine immunogenicity in immunocompetent or mildly immunosuppressed individuals. These results, which derive from within-cohort analyses and do not rely on direct comparisons between heterogeneous vaccine populations, support the role of TTV as a marker of immune status along a continuum of immunosuppression, with predictive value likely confined to populations with more severe immune impairment.

Schlagwörter

Stichwörter der Autor:innen

DGVImmune responsesMPXVMVA-BNTAK-003TTV

Autor:innen und Institutionen

  • Laboratory of Virology and Laboratories of Biosecurity, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.
  • Cellular Immunology and Pharmacology Laboratory, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.
  • Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.
  • Clinical and Research Department, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.
  • North-Western Tuscany Blood Bank, Pisa University Hospital, 56126 Pisa, Italy.

ORCID-Profile: Claudia Minosse, Pietro Giorgio Spezia, Giulia Matusali, Francesca Colavita, Stefania Notari, Alessandro Rosario Cavasio, Valentina Mazzotta, Luigi Rosa, Eleonora Cimini, Delia Goletti, Emanuele Nicastri, Andrea Antinori, Fabrizio Maggi

Förderung

  • Ministry of Health
  • European Union Framework Programme for Research and Innovation Horizon 2020
  • Italian Ministry of Health
  • European Union

Zitieren

APA

Minosse, C., Spezia, P. G., Belladonna, S., Bettini, A., Matusali, G., Colavita, F., Notari, S., Petrone, L., Tiberi, M., Cavasio, A. R., Mazzotta, V., Rosa, L., Cimini, E., Focosi, D., Goletti, D., Nicastri, E., Antinori, A., & Maggi, F. (2026). TTV Viremia and Immune Responses Following Vaccination Against Mpox and Dengue Viruses. Vaccines, 14(5), 441. https://doi.org/10.3390/vaccines14050441

Vancouver

Minosse C, Spezia PG, Belladonna S, Bettini A, Matusali G, Colavita F, et al. TTV Viremia and Immune Responses Following Vaccination Against Mpox and Dengue Viruses. Vaccines. 2026;14(5):441. doi:10.3390/vaccines14050441

BibTeX
@article{Minosse2026,
  author = {Minosse, Claudia and Spezia, Pietro Giorgio and Belladonna, Sara and Bettini, Aurora and Matusali, Giulia and Colavita, Francesca and Notari, Stefania and Petrone, Linda and Tiberi, Marta and Cavasio, Alessandro Rosario and Mazzotta, Valentina and Rosa, Luigi and Cimini, Eleonora and Focosi, Daniele and Goletti, Delia and Nicastri, Emanuele and Antinori, Andrea and Maggi, Fabrizio},
  title = {TTV Viremia and Immune Responses Following Vaccination Against Mpox and Dengue Viruses},
  journal = {Vaccines},
  year = {2026},
  volume = {14},
  number = {5},
  pages = {441},
  doi = {10.3390/vaccines14050441}
}
Kostenlos starten →